Published On: Sun, Jun 8th, 2014

China fast tracks D-Pharm epilepsy drug

Jiangsu NHWA Pharmaceutical is developing DP-VPA in China under a strategic agreement.

D-Pharm

D-Pharm Ltd. (TASE: DPRM) has obtained fast track status from the China’s Food and Drug Administration (CFDA) for its epilepsy treatment, DP-VPA. D-Pharm is jointly developing the drug in China with its local partner, Jiangsu NHWA Pharmaceutical Co. Ltd., under a strategic agreement signed in 2011. D-Pharm has the right to use the Chinese data to support its development program for DP-VPA in North America and Europe.

D-Pharm discovered and is developing DP-VPA, a novel drug derived from the generic drug valproic acid, sales of which peaked at $1 billion for the treatment of epilepsy, migraine, and bipolar disorder. DP-VPA has already completed a first Phase II clinical trial.

“I’m delighted with the progress made by our partners NHWA. Advancement of DP-VPA in China is a great way to boost our own development program for DP-VPA in major pharmaceutical markets, ” said D-Pharm CEO Dr. Alex Kozak. “It enables the most efficient and effective introduction of our innovative product to the important and rapidly developing Chinese market, a feat clearly best accomplished by a competent local partner.”

NHWA is developing and will manufacture, register and sell DP-VPA for epilepsy in China, Hong Kong and Macau, in compliance with US Food and Drug Administration (FDA) standards. D-Pharm will receive milestone payments upon achievements of the development and commercial goals, as well as royalty payments from sales of DP-VPA.

Read more about: , ,

Wordpress site Developed by Fixing WordPress Problems